ANAB Collar Strategy
ANAB (AnaptysBio, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
ANAB (AnaptysBio, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.69B, a beta of 0.40 versus the broader market, a 52-week range of 11.404-72.36, average daily share volume of 704K, a public-listing history dating back to 2017, approximately 104 full-time employees. These structural characteristics shape how ANAB stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.40 indicates ANAB has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a collar on ANAB?
A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot.
ANAB snapshot
As of August 14, 2026, spot at $58.08, ATM IV 70.00%, IV rank 10.02%, expected move 20.07%. The collar on ANAB below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this collar structure on ANAB specifically: IV regime affects collar pricing on both sides; compressed ANAB IV at 70.00% typically pushes the short call premium to roughly offset the long put cost, with a market-implied 1-standard-deviation move of approximately 20.07% (roughly $11.66 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ANAB expiries trade a higher absolute premium for lower per-day decay. Position sizing on ANAB should anchor to the underlying notional of $58.08 per share and to the trader's directional view on ANAB stock.
ANAB collar setup
The ANAB collar below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ANAB at $58.08 on that close, the first option leg uses a $60.98 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ANAB chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ANAB shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $58.08 | long |
| Sell 1 | Call | $60.98 | N/A |
| Buy 1 | Put | $55.18 | N/A |
ANAB collar risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium.
ANAB collar payoff curve
Modeled P&L at expiration across a range of underlying prices for the collar on ANAB. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use collar on ANAB
Collars on ANAB hedge an existing long ANAB stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
ANAB thesis for this collar
The market-implied 1-standard-deviation range for ANAB extends from approximately $46.42 on the downside to $69.74 on the upside. A ANAB collar hedges an existing long ANAB position with a protective put while financing the put cost via a short call; when the premiums roughly offset, the collar acts as a near-zero-cost insurance band around the current spot. Current ANAB IV rank near 10.02% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ANAB at 70.00%. As a Healthcare name, ANAB options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ANAB-specific events.
ANAB collar positions are structurally neutral (protective); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ANAB positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ANAB alongside the broader basket even when ANAB-specific fundamentals are unchanged. Always rebuild the position from current ANAB chain quotes before placing a trade.
Frequently asked questions
- What is a collar on ANAB?
- A collar on ANAB is the collar strategy applied to ANAB (stock). The strategy is structurally neutral (protective): A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot. With ANAB stock at $58.08 on the most recent close, the strikes shown on this page are snapped to the nearest listed ANAB chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are ANAB collar max profit and max loss calculated?
- Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium. For the ANAB collar priced from the end-of-day chain at a 30-day expiry (ATM IV 70.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ANAB collar?
- The breakeven for the ANAB collar priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The ANAB market-implied 1-standard-deviation expected move in the same options snapshot is approximately 20.07%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a collar on ANAB?
- Collars on ANAB hedge an existing long ANAB stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
- How does current ANAB implied volatility affect this collar?
- ANAB ATM IV is at 70.00% with IV rank near 10.02%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.